Retatrutide activates GLP-1, GIP, and glucagon receptors in one molecule, distinguishing it from single agonists like semaglutide and dual agonists like tirzepatide
Choice-impulsivity in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): A meta-analytic review
Eli Lillys GLP-1 offering, tirzepatide, launched shortly after (as Mounjaro for T2D in 2022 and Zepbound for obesity in 2023), demonstrated greater HbA1c reduction and up to a 20% placebo-adjusted weight loss
A systematic review and meta-analysis"
Its not about hitting the highest dose, its about finding the lowest effective dose that: keeps your appetite consistently controlled supports long-term weight stability maintains your metabolic improvements minimizes side effects In other words, your maintenance dose is your sweet spot. Most Common Tirzepatide Maintenance Doses (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) These ranges represent the doses most people settle into long-term: These are not recommendations, but real-world patterns
Who Could Benefit